Testing ES502 for Advanced Pancreatic and Other Cancers
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This early-stage trial tests a new drug called ES502 for patients with advanced cancers (including pancreatic cancer) that have a specific genetic mutation and certain immune markers. The study aims to find the right dose and see if it helps shrink tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have advanced cancer (pancreatic, colorectal, lung, or other types) that hasn't responded to standard treatment or for which no standard treatment exists
- Your tumor has a RAS G12V mutation and specific HLA immune markers
- You have a tumor sample available from the past 5 years for genetic testing
- Your overall health is good enough for treatment (ECOG score 0–1, expected to live longer than 3 months)
- Your blood counts, liver, kidney, and heart function are adequate
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunotherapy for people with advanced pancreatic cancer that cannot be removed by surgery or has spread. It may be an option if you have already tried at least one previous treatment or if you have not had any treatment yet, depending on the study group.
This trial tests personalized therapies for people with advanced pancreatic cancer that has spread or cannot be removed. It aims to find the best treatment based on your tumor's unique features.
This trial tests a new drug combination for pancreatic cancer that has not been treated before. It may help shrink tumors or make surgery possible for people with advanced or borderline resectable disease.
This trial tests a cancer vaccine (ELI-002 7P) for people with pancreatic cancer that hasn't spread to other parts of the body. It may be given alone or with another drug (tislelizumab) that helps the immune system fight cancer. The goal is to see if these treatments can help keep the cancer from coming back after surgery or chemotherapy.
This study tests a new drug called HRS-7058 in patients with pancreatic cancer that has spread or cannot be removed by surgery. You may qualify if your cancer has already been treated with at least one prior therapy and you have measurable disease on imaging.
This trial tests a new immune cell therapy (EGFRBi armed PBMC) for people with advanced pancreatic cancer that can't be removed by surgery. It aims to see if this treatment can help control the cancer after you've already tried at least one type of chemotherapy and your disease is stable or better.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.